Provided by Tiger Trade Technology Pte. Ltd.

Greenwich Lifesciences Inc

29.00
+3.8115.13%
Post-market: 28.09-0.9100-3.14%19:38 EST
Volume:302.89K
Turnover:8.15M
Market Cap:401.78M
PE:-19.86
High:29.00
Open:25.40
Low:24.76
Close:25.19
52wk High:34.10
52wk Low:7.78
Shares:13.85M
Float Shares:6.37M
Volume Ratio:0.96
T/O Rate:4.75%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4606
EPS(LYR):-1.2132
ROE:-543.43%
ROA:-254.19%
PB:183.88
PE(LYR):-23.90

Loading ...

Company Profile

Company Name:
Greenwich Lifesciences Inc
Exchange:
NASDAQ
Establishment Date:
2006
Employees:
6
Office Location:
Building 14,3992 Bluebonnet Dr.,Stafford,Texas,United States
Zip Code:
77477
Fax:
- -
Introduction:
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

Directors

Name
Position
David B. McWilliams
Chairman and Independent Director
Snehal S. Patel
Chief Executive Officer and Chief Financial Officer and Director
Eric Rothe
Independent Director
F. Joseph Daugherty
Chief Medical Officer and Director
Kenneth Hallock
Independent Director

Shareholders

Name
Position
Snehal S. Patel
Chief Executive Officer and Chief Financial Officer and Director
F. Joseph Daugherty
Chief Medical Officer and Director